BriaCell Therapeutics 

0
67
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-23.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8BT.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is involved in developing cancer immunotherapies, directly competing with BriaCell's focus on advanced breast cancer treatments.
Merck
MRK
Mkt Cap368.89B
Merck's strong presence in the oncology sector, especially with its blockbuster drug Keytruda, makes it a direct competitor in cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb has a robust lineup of cancer drugs and is actively involved in developing immunotherapies, competing in the same space as BriaCell.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, with its acquisition of Kite Pharma, has become a key player in the cancer immunotherapy market, competing with BriaCell's therapies.
Novartis
NVS
Mkt Cap303.67B
Novartis is a major pharmaceutical company with a strong emphasis on oncology, including breast cancer treatments, making it a competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's focus on innovative treatments for cancer places it in direct competition with BriaCell, especially in the development of biologics.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, is a leader in cancer therapeutics, including breast cancer, competing with BriaCell's targeted approach.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a significant portfolio in oncology, including breast cancer treatments, making it a competitor in the same therapeutic area as BriaCell.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals' work in developing monoclonal antibodies for cancer treatment puts it in competition with BriaCell's immunotherapy approach.
Iovance Biotherapeutics
IOVA
Mkt Cap3.84B
Iovance Biotherapeutics focuses on T-cell-based therapies for cancer, competing in the innovative immunotherapy space alongside BriaCell.

About

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Show More
CEO
William V. Williams
Employees
31
Country
Canada
ISIN
CA1079303071
WKN
000A41DJH

Listings

0 Comments

Share your thoughts

FAQs

What is BriaCell Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange BriaCell Therapeutics stocks are traded under the ticker 8BT.STU.
What is BriaCell Therapeutics revenue for the last year?▼
BriaCell Therapeutics revenue for the last year amounts to 0 EUR.
What is BriaCell Therapeutics net income for the last year?▼
8BT.STU net income for the last year is -23.89M EUR.
How many employees does BriaCell Therapeutics have?▼
As of November 2, 2026, the company has 31 employees.
In which sector is BriaCell Therapeutics located?▼
BriaCell Therapeutics operates in the Health & Wellness sector.
When did BriaCell Therapeutics complete a stock split?▼
The last stock split for BriaCell Therapeutics was on August 25, 2025 with a ratio of 1:10.
Where is BriaCell Therapeutics headquartered?▼
BriaCell Therapeutics is headquartered in WEST VANCOUVER, Canada.